ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma ecology genetics genomics

Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
A colorful mandarinfish on a reef
Genome Spotlight: Mandarinfish (Synchiropus splendidus)
Christie Wilcox, PhD | Oct 28, 2021 | 3 min read
The high-quality genome sequence sheds light on the colorful nature of these popular aquarium fish.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
A fruit bat in the hands of a researcher
How an Early Warning Radar Could Prevent Future Pandemics
Amos Zeeberg, Undark | Feb 27, 2023 | 8 min read
Metagenomic sequencing can help detect unknown pathogens, but its widespread use faces challenges.
"Big Cross" Lands Sticklebacks in the Spotlight
David Secko | Nov 7, 2004 | 5 min read
Marine threespine sticklebacks haven't morphologically changed in an estimated 10 million years, but their freshwater offshoots show no signs of slowing down. These 5-cm-long, freshwater fish have undergone a recent evolutionary change, variably losing their calcified body armor and retractable pelvic and dorsal spines. Remarkably, isolated marine and freshwater sticklebacks can be hybridized in the laboratory, a fact that is allowing researchers to analyze the genetics behind their natural dive
Pufferfish Genomes Probe Human Genes
Ricki Lewis | Mar 17, 2002 | 7 min read
It may be humbling to think that humans have much in common with pufferfish, but at the genome level, the two are practically kissing cousins. "In terms of gene complement, we are at least 90% similar—probably higher. There are big differences in gene expression levels and alternate transcripts, but if you're talking about diversity, number and types of proteins, then it's pretty difficult to tell us apart," says Greg Elgar, group leader of the Fugu genome project at the Medical Research C
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Genetic Parasites and a Whole Lot More
Barry Palevitz | Oct 15, 2000 | 10+ min read
Photo: Ori Fragman, Hebrew University Hordeum spontaneum, the plant studied for BARE-1 retroelements. With genome sequences arriving almost as regularly as the morning paper, the public's attention is focused on genes--new genes to protect crops against pests; rogue genes that make bacteria resistant to antibiotics; faulty genes that, if fixed, could cure diseases such as muscular dystrophy. What many people don't realize is that genes account for only part of an organism's DNA, and in many c
Clinton, Blair Stoke Debate on Gene Data
Ricki Lewis | Apr 2, 2000 | 7 min read
President Bill Clinton and British Prime Minister Tony Blair's brief statement of March 14 supporting free access to human genome information unleashed a slew of clichés, including "too little too late" and "water under the bridge." But initial misinterpretation of the statement led to a temporary slide in biotech stocks. By the end of the day, Celera Genomics Corp. of Rockville, Md., had dropped 19 percent, while Incyte Pharmaceuticals of Palo Alto, Calif., plummeted 27 percent. Even thoug
Capsule Reviews
Bob Grant | May 1, 2015 | 3 min read
The Genealogy of a Gene, On the Move, The Chimp and the River, and Domesticated

Run a Search

ADVERTISEMENT